Commission Implementing Regulation (EU) 2026/1810 of 24 July 2026 amending Implementing Regulation (EU) 2025/901 as regards the addition of the substances ketoconazole, midazolam and sevoflurane, and Regulation (EC) No 1950/2006 as regards the deletion of the substances digoxin, dorzolamide, griseofulvin, imipramine, ketoconazole, phenytoin and ticarcillin
Preamble 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC ( 1 ) , and in particular Article 115(5) thereof,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) Commission Implementing Regulation (EU) 2025/901 ( 2 ) establishes a list of substances which are essential for the treatment of equine species, or which bring added clinical benefit compared to other treatment options available for equine species and for which the withdrawal period for equine species is to be six months.
recital 2recital 2
(2) Under Implementing Regulation (EU) 2025/901, a substance only qualifies as an ‘essential substance’ where no satisfactory alternative for the treatment or diagnosis of an indication is available and where the condition would, if untreated, create unnecessary suffering for the animal. A substance only qualifies as ‘bringing added clinical benefit’ where it provides a clinically relevant advantage based on improved efficacy or safety or a major contribution to treatment or diagnosis. This may be the result, inter alia, of different modes of action, different pharmacokinetic or pharmacodynamic profiles, different lengths of treatment or different routes of administration.
recital 3recital 3
(3) Since the adoption of Implementing Regulation (EU) 2025/901, new information has emerged indicating that griseofulvin, ketoconazole, midazolam, rifampicin and sevoflurane may meet the criteria for essential substances or bring added clinical benefit compared to other treatment options available for equine species when used for specific indications.
recital 4recital 4
(4) The Commission requested ( 3 ) the European Medicines Agency (‘the Agency’) to examine that information and to provide guidance in accordance with Article 141(1), point (f), of Regulation (EU) 2019/6. In its resulting guidance ( 4 ) , the Agency concluded that the substances griseofulvin, ketoconazole, midazolam and sevoflurane can be considered essential or to bring added clinical benefit compared to other treatment options available for equine species when used for the indications proposed.
recital 5recital 5
(5) As part of the Commission’s request, the Agency also assessed whether a withdrawal period of six months would be sufficient in respect of the equine animals treated with the substances found to be essential or to bring added clinical benefit for the proposed indications. The Agency could not exclude risks associated with griseofulvin and ketoconazole when used for all or for some of the indications proposed for each of those substances, even if a withdrawal period of six months is observed. The Agency’s scientific advice ( 5 ) , which informed Implementing Regulation (EU) 2025/901, reached similar conclusions in respect of digoxin, dorzolamide, imipramine and phenytoin.
recital 6recital 6
(6) Commission Regulation (EC) No 1950/2006 ( 6 ) continues to apply until 21 May 2027. To maintain a high level of consumer safety, it is appropriate to discontinue the use of those substances in accordance with Regulation (EC) No 1950/2006.
recital 7recital 7
(7) Commission Implementing Regulation (EU) 2022/1255 ( 7 ) reserved the class of carboxypenicillins for the treatment of certain infections in humans. The use of the substance ticarcillin in animals is therefore not allowed in the Union. Since Regulation (EC) No 1950/2006 applies until 21 May 2027 and to ensure legal certainty for the competent authorities, veterinarians, animal keepers and economic operators concerned, it is appropriate to remove that substance from the list in the Annex to Regulation (EC) No 1950/2006.
recital 8recital 8
(8) Implementing Regulation (EU) 2025/901 and Regulation (EC) No 1950/2006 should therefore be amended accordingly.
recital 9recital 9
(9) To avoid consumer safety risks, to increase the availability of medicinal products to food-producing animals of the equine species and to avoid unacceptable suffering of those animals, this Regulation should enter into force on the day following that of its publication in the Official Journal of the European Union .
recital 10recital 10
(10) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
Article 1Amendment to Implementing Regulation (EU) 2025/901
The Annex to Implementing Regulation (EU) 2025/901 is replaced by the text in the Annex to this Regulation.
Article 2Amendment to Regulation (EC) No 1950/2006
The entries for the substances digoxin, dorzolamide, griseofulvin, imipramine, ketoconazole, phenytoin and ticarcillin in the Annex to Regulation (EC) No 1950/2006 shall be deleted.
Article 3Entry into force
This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union .
Annex 1ANNEX
Groups of substances
I. Anaesthetics
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Oxybuprocaine a Local topical anaesthesia for use in eyes None identified Wide clinical experience Prilocaine b Local topical anaesthesia prior to intravenous injection or catheterisation Lidocaine In specific preparations (eutectic mixture of local anaesthetics), for topical application to skin; can be used to facilitate intravenous injection or catheterisation Sevoflurane b Mask induction of anaesthesia in foals Isoflurane Better suited for mask induction as less pungent than the alternative ( 1 ) Active substances identified with an ‘a’ are essential substances. Substances identified with a ‘b’ are substances which bring added clinical benefit.
II. Analgesics
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Bromfenac b Treatment of uveitis and ocular inflammation Systemic nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. flunixin); topical (ocular) ketorolac Topical NSAIDs may result in less patient discomfort, reduced postoperative inflammation, prevention of miosis, and improvements in visual acuity in the early postoperative period Fentanyl b Multimodal approach for moderate to severe acute painful conditions Butorphanol, morphine Produces better analgesia than certain other opioids and can be used for very painful conditions; recognised value for use in multi-modal approaches Ketorolac b Treatment of eye pain and inflammation Systemic NSAID therapy (e.g. flunixin) Formulated for local application Methocarbamol b As part of treatment protocols in severe painful muscle spasms or severe muscle inflammation conditions Systemic NSAIDs (e.g. flunixin) Potent skeletal muscle relaxation; specific action on the internuncial neurons of the spinal cord to reduce acute skeletal muscle spasms without a concomitant alteration in muscle tone Morphine b Analgesia Butorphanol, fentanyl More potent than other analgesics Triamcinolone acetonide b Treatment of joint inflammation Methylprednisolone Less harmful effects on cartilage metabolism
III. Antimicrobials
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages I. Antibiotics Amikacin b Treatment of septicemia in horses and foals Gentamicin, ceftiofur Better safety profile in the target animal Azithromycin b Treatment of Rhodococcus equi infections susceptible to azithromycin Clarithromycin, erythromycin, gamithromycin, tulathromycin, doxycycline Added clinical benefit in cases of Rhodococcus equi infections in foals that can be resolved as monotherapy or in combination with doxycycline Clarithromycin b Treatment of Rhodococcus equi infections susceptible to clarithromycin Azithromycin, erythromycin, gamithromycin, tulathromycin, doxycycline More active against Rhodococcus equi in vitro than erythromycin or azithromycin; achieves greater concentrations in pulmonary epithelial lining fluid and alveolar macrophages than either erythromycin or azithromycin, though the half-life is shorter Fusidic acid b Topical treatment of eye infections caused by gram-positive bacteria susceptible to fusidic acid Ofloxacin, moxifloxacin Broad spectrum for treatment of gram-positive infections; primary choice in superficial, uncomplicated corneal ulcers and acute conjunctivitis in horses Moxifloxacin b Topical treatment of external eye infections caused by gram-positive cocci, gram-negative, atypical and anaerobic bacteria, such as Pseudomonas aeruginosa, susceptible to moxifloxacin Ofloxacin Advantageous pharmacokinetic profile; spectrum of activity includes gram-positive cocci and anaerobic bacteria that may be resistant to other quinolones Ofloxacin b Treatment of external eye infections caused by gram-positive and gram-negative micro-organisms susceptible to ofloxacin Moxifloxacin Clinical experience; penetrates the entire cornea up to the anterior chamber of the eye Polymyxin B b Treatment of bacterial keratitis, topical use Ofloxacin, moxifloxacin Effective alternative to systemic treatments; different mechanism of action to other topical alternatives II. Antifungals Amphotericin B a Treatment of fungal pneumonia, systemic use None identified Treatment of choice Ketoconazole b Adjunctive therapy in the treatment of guttural pouch mycosis, topical use Enilconazole Less irritant compared to the alternative; formulated for local application Miconazole b Treatment of fungal infection of the eye Natamycin, nystatin, voriconazole Broad spectrum of activity; less irritant compared to other topical antifungals Nystatin b Treatment of fungal and yeast infections of the eye and genital tract Miconazole Treatment of choice for yeast infections Voriconazole b Treatment of fungal keratitis, topical use Miconazole Broad spectrum of activity III. Antivirals Aciclovir b Treatment of cases of equine herpes virus infection associated with complications, topical use only Ganciclovir Treatment of choice for ocular ulcers when the implication of a viral pathogen is suspected Ganciclovir b Treatment of cases of equine herpes virus infection associated with complications, topical use Aciclovir, valaciclovir Wealth of evidence for the treatment of different virus-types causing herpetic infections Valaciclovir b Treatment of cases of equine herpes virus infections, oral use Aciclovir Better pharmacokinetic profile and a different route of administration
IV. Substances for respiratory disorders
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Ambroxol b Stimulation of surfactant in premature foals Steroids, bromhexine, dembrexine, surfactant transfer from healthy donor Preferred clinical choice for premature foals Fluticasone b Control of allergic pulmonary disease including mild to moderate cases of equine asthma and subtypes via inhalation Beclomethasone Inhalation leads to less adreno-cortical suppression, quicker rebound after therapy ends and fewer systemic side effects than systemic corticosteroid therapy because of its limited systemic absorption; especially indicated for control of mild-moderate and refractory severe asthma as well as long-term maintenance therapy Ipratropium bromide b As a bronchodilator in horses with mild-moderate asthma Clenbuterol Anticholinergic action, as an alternative to beta-agonists Oxymetazoline b Treatment of nasal oedema Phenylephrine Alpha-adrenoceptor agonist with strong vasoconstrictive properties and longer acting effect Phenylephrine b Treatment of nasal oedema Oxymetazoline Reduces the need for insertion of nasal tubes during recovery
V. Substances for cardiology
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Amiodarone b Systemic and oral treatment of atrial fibrillation, supraventricular and ventricular tachycardias Quinidine sulphate/gluconate, sotalol, verapamil Different mode of action: class III anti-dysrhythmic Propafenone b Treatment of ventricular tachycardia and ventricular tachyarrhythmia Quinidine sulphate/gluconate Different mode of action: sodium channel antagonist that decreases heart excitability Quinapril a Treatment of heart failure; cardiovascular protection in horses with atrial fibrillation (AF) or mitral regurgitation (MR) None identified Different mode of action: angiotensin-converting-enzyme (ACE) inhibitor Quinidine sulphate/gluconate b Treatment of cardiac arrhythmias Amiodarone, sotalol, verapamil Treatment of choice for atrial fibrillation Sotalol b Long-term treatment of cardiac arrhythmias Amiodarone, quinidine sulphate/gluconate More suitable in horses requiring long-term anti-arrhythmic therapy; less adverse events than amiodarone Verapamil b Treatment of supraventricular arrhythmias Amiodarone, quinidine sulphate/gluconate, sotalol Different mode of action: calcium channel blocker
VI. Substances for diagnostic procedures
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Barium sulfate a Enhanced gastrointestinal tract visualisation during radiographic examinations None identified No satisfactory alternative treatment for enhanced gastrointestinal tract visualisation during radiographic examinations Fluorescein b Diagnosing corneal keratitis or ulceration, topical use Rose bengal Diagnostic tool of choice when a viral culture is needed afterwards Iohexol a Contrast agent for lower urinary tract radiography, arthrography, myelography, sino- or fistulography and dacryocystography None identified Non-ionic, water-soluble contrast agent Phenylephrine a Diagnosing grass sickness None identified Ancillary diagnostic approach to equine grass sickness polyneuropathy Rose bengal b Diagnosing corneal keratitis or ulceration, topical use Fluorescein Diagnostic tool of choice for diagnosing eye keratitis/ulcers Thyrotropin releasing hormone a Diagnosing pituitary pars intermedia dysfunction None identified No satisfactory alternatives for diagnosing pituitary pars intermedia dysfunction
VII. Substances for gastrointestinal disorders
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Metoclopramide b Treatment of post-operative ileus Intravenous fluid substitution, painkillers (e.g. flunixin), lidocaine Prokinetic drug Misoprostol b Treatment of gastric glandular disease and colitis Omeprazole, sucralfate Superior to omeprazole for the treatment of equine gastric glandular disease Phenylephrine a Treatment of nephrosplenic entrapment None identified Clinical value in the resolution of nephrosplenic entrapment; causes a dose-dependent splenic contraction Ranitidine b Treatment of gastric ulcers in critically ill neonates, intravenous use Omeprazole The intravenous route of administration brings added clinical benefit over other oral antiulcer medications Sucralfate b Treatment and prevention of gastric ulcers in horses Omeprazole Different mode of action than omeprazole (mucosal adherent), which provides physical lesion stabilisation
VIII. Substances for metabolic disorders
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Insulin b As an aid in the treatment of hyperlipidaemia unresponsive to glucose therapy or severe hyperlipidaemia, used in combination with glucose and other therapies Diagnosing metabolic disorders (e.g. insulin resistance associated with equine metabolic syndrome or pituitary pars intermedia dysfunction) Low-molecular weight heparin can be used for cases of hyperlipidaemia Insulin is the preferred clinical choice
IX. Substances for musculoskeletal disorders
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Atracurium b Inducing muscle paralysis under general anaesthesia Cisatracurium, guaifenesin Brings added clinical benefit in horses under general anaesthesia in cases where increased muscle relaxation is necessary such as ophthalmic surgeries, certain orthopaedic repairs and when deep access to the abdominal cavity is needed. Cisatracurium b Inducing muscle paralysis under general anaesthesia Atracurium, guaifenesin Brings added clinical benefit in horses under general anaesthesia in cases where increased muscle relaxation is necessary such as ophthalmic surgeries, certain orthopaedic repairs and when deep access to the abdominal cavity is needed. Dantrolene sodium b Prevention of rhabdomyolysis Prevention of malignant hyperthermia during anaesthesia NSAIDs, intravenous fluids, vitamin E/selenium Efficacious as preventative, inhibiting the release of calcium from the sarcoplasmic reticulum and thus causing dissociation of excitation-contraction coupling Edrophonium a Reversing the effects of atracurium muscle paralysis None identified Cholinesterase inhibitor, essential for reversal of neuromuscular blockade; least side effects of the cholinesterase inhibitors in horses Guaifenesin b Induction and maintenance of general anaesthesia in field conditions Atracurium, cisatracurium Particularly indicated in field (non-hospital) conditions where anaesthesia may be necessary; the reduced cardiopulmonary depressive effects facilitate safe anaesthesia without advanced monitoring equipment or mechanical ventilation
X. Substances for nervous system disorders
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Diazepam a Short-term anti-convulsant for treatment of seizures None identified Second-generation antiseizure Midazolam a Short-term anti-convulsant for treatment of seizures None identified Second-generation antiseizure
XI. Substances for ophthalmology
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Acetazolamide b Treatment of glaucoma, oral use Phenylephrine Its mechanism of action as carbonic anhydrase inhibitor Cyclopentolate b Mydriatic agent Atropine, phenylephrine Induces significant mydriasis without affecting tear production, intraocular pressure, digestive function (i.e. gut motility and faeces production), or heart rate Cyclosporine A b Treatment of autoimmune diseases of the eye Topical steroids Immunosuppressive effect by inhibiting T-lymphocyte proliferation and reducing cytokine gene expression Phenylephrine b Treatment of glaucoma and epiphora Atropine and tropicamide It does not (or only slightly) increase intra ocular pressure Synephrine b Treatment of the mucous membranes of the eye as a decongestant Phenylephrine, tetryzoline Fast local effect; enhances penetration of local therapy, providing synergistic effects with e.g. local antimicrobial therapy Tetryzoline b Treatment of the mucous membranes of the eye as a decongestant Phenylephrine, synephrine Fast local effect Timolol maleate b Treatment of glaucoma, topical use Acetazolamide Its specific mode of action as a non-selective beta-adrenergic receptor blocking agent, provides for an important therapeutic choice in the treatment of glaucoma Triamcinolone acetonide b Treatment of recurrent uveitis in cases that are refractory to other treatments Atropine, tropicamide Effective, low-morbidity treatment in cases that are refractory to other treatments Tropicamide b Treatment of recurrent uveitis Atropine, cyclopentolate, triamcinolone acetonide Rapid onset of action
XII. Substances for sedation and premedication (and antagonism)
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Acepromazine b For a multimodal approach for tranquilisation and premedication in combination with other sedatives Detomidine, romifidine, xylazine, diazepam The mode of action of acepromazine and its unique quality of sedation cannot be produced by alpha-2 agonist sedatives or benzodiazepines Atipamezole a Reversing the effects of alpha-2 agonists None identified Reverses sedative and analgesic effects and adverse cardiovascular reactions Dexmedetomidine b Sedation or general anaesthesia as part of partial or total intravenous anaesthesia protocols Detomidine, romifidine, xylazine, diazepam The most selective alpha-2 agonist; short half-life and rapid redistribution, which particularly favour its use as a continuous-rate infusion Diazepam b Premedication and induction of anaesthesia, mild tranquilisation with minimal cardiovascular and respiratory side effects Acepromazine, detomidine, romifidine, xylazine The mode of action (at gamma-aminobutyric acid (GABA) receptor) provides unique tranquilisation without cardiorespiratory depression that cannot be produced by alpha-2 agonist sedatives (detomidine, romifidine and xylazine) or acepromazine Midazolam b Premedication and induction of anaesthesia, mild tranquilisation with minimal cardiovascular and respiratory side effects Acepromazine, detomidine, romifidine, xylazine The mode of action (at GABA receptor) provides unique tranquilisation without cardiorespiratory depression that cannot be produced by alpha-2 agonist sedatives (detomidine, romifidine and xylazine) or acepromazine Flumazenil a Intravenous reversal agent for benzodiazepine effect during recovery from Total Intravenous Anaesthesia (TIVA) techniques None identified Antagonist that competitively inhibits the benzodiazepine binding site at the GABA receptor Naloxone a Reversal of opioid effects during emergencies None identified No alternatives available Propofol b Induction of anaesthesia in foals via intravenous administration Isoflurane Improvement in cardiovascular stability and quality of recovery over inhalation anaesthesia in foals
XIII. Substances for systemic disorders
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Allopurinol b Neonatal ischaemia reperfusion injury Vitamin E Different mode of action in inhibiting the formation of reactive oxygen species (ROS) than vitamin E Dalteparin b Anticoagulant Heparin Reduction in molecular size is associated with a loss of thrombin inhibitory activity, but conversely an increase in factor Xa (FXa) inhibition compared to unfractionated heparin Dobutamine b Management of hypotension under general anaesthesia Ephedrine First-line medication for the treatment of hypotension in adult equines under general anaesthesia Dopamine a As part of a treatment protocol for acute kidney injury/renal failure only None identified Low doses have been shown to cause renal vasodilation, increased renal blood flow, and increased urine production without systemic cardiovascular effects in conscious healthy horses Ephedrine b Treatment of hypotension under general anaesthesia Dobutamine Used to treat hypotension in adult equines under general anaesthesia where dobutamine is ineffective. Different mode of action to dobutamine with a more direct effect on cardiac contractility Gelatinpolysuccinate b Addressing long-term hypovolaemia resulting from conditions like e.g. low albumin Crystalloids Colloids are larger molecules compared to crystalloids, thus stay longer in the intravascular space, which is an advantage for correcting hypovolemia from e.g. hypoalbuminemia Glycopyrrolate b Treatment and prevention of bradycardia Atropine Minimal central effect; suitable in conscious horses, before and after anaesthesia Noradrenaline / norepinephrine b Treatment of early septic shock Supporting cardiovascular function in critically ill foals Dobutamine, dopamine In compromised (sick) foals it is generally the only catecholamine effective in treatment of hypotension Vasopressin b Treatment of circulatory collapse in foals and adult horses Epinephrine, dopamine, dobutamine Alternative in cases where standard catecholamine therapies like dopamine, dobutamine, epinephrine are ineffective or require potentiation to restore vascular tone in refractory vasodilatory shock states
XIV. Substances for tumours
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Imiquimod a Treatment of sarcoids None identified Current research suggests that equine sarcoids likely result from a complex interaction including host immune system dysfunction
XV. Miscellaneous
Active substance ( 1 ) Indications Identification of alternatives Explanation of use / specific advantages Cetirizine b Treatment of conditions where an antihistamine is deemed necessary Chlorphenamine Second-generation histamine-1 (H1) receptor inverse agonists are alternatives with fewer central nervous system (CNS) (sedative) side effects Domperidone b Treatment of agalactia/dysgalactia in mares Sulpiride Its ability to stimulate prolactin secretion in situations of dopaminergic inhibition Sulpiride b Treatment of agalactia/dysgalactia in mares Domperidone Its ability to stimulate prolactin secretion in situations of dopaminergic inhibition